anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A recent Cochrane intervention review revealed evidence for the effectiveness of using speech and language therapy (SLT) for people with aphasia following stroke in terms of functional communication, receptive and expressive language. The authors highlight positive effects of higher training frequency on functional outcome. Also other authors emphasizes the importance of training frequency. In the meta-analysis with 968 patients the authors found that only intervention studies with more than five hours training per week lead to positive effects on speech and language function. They highlighted that it might be better to train short but with a high frequency than long with a low frequency. While some researchers emphasizes the benefit of early intervention, several studies found that also chronic stroke patients can benefit from intensive SLT. One possible approach to increase training frequency and duration is to complement therapist delivered usual care SLT (ucSLT) with telerehabilitation SLT (teleSLT) delivered in the patient's home.

Aphasia is frequently accompanied by deficits of working memory (WM), speed of processing (SP) and executive functions (EF). Recent studies suggest that these cognitive abilities can play a role in sentence comprehension and production by individuals with aphasia and that WM, SP and EF can be enhanced with intensive practice. The authors suggest that SLT therapy should be accompanied with cognitive training (CT). It remains however unclear what percentage of the training time should be devoted to SLT and to cognitive training respectively. For the current study the investigators will use two combinations of teleSLT and telerehabilitation cognitive training (teleCT), where one combination will have a higher percentage of time devoted to teleSLT and the other a higher percentage devoted to teleCT. The latter will serve as the control group to examine the effect of teleSLT.
An adhesive preparation is made by suspending a hygroscopic, transdermally biologically active substance in a solution of a water insoluble but water permeable cellulose ether in an inert organic solvent.  In one example 5 grams of ethyl cellulose is dissolved in a mixture of 8 volumes of dry carbon tetrachloride and 2 volumes of dry chloroform.  Twenty grams of dry powdered autolytic tuberculin is stirred in to give a uniform suspension. This last substance may be prepared as described in Specification 632,672.  The preparation may be applied to the skin and allowed to dry or it may be dried to form a film which is cut to convenient sizes and stored.  In the latter form it is applied to the skin by softening with a drop of chloroform.
A method and a device for collecting data are provided to upload the data to a data center without any user operation if the data is stored over the first reference value and minimize power consumption of a data collector by periodically detecting a pilot signal received from a wireless data transceiving station. A measuring module(301) measures and stores the data to a storing part. A communicating module(302) automatically transmits the stored data to the wireless data transceiving station if the quantity of the data stored in the storing part is over the first reference value. The communicating module includes a receiver module(303) operated if the quantity of the data stored in the storing part is over the first reference value. The receiver module operates the communicating module if the pilot signal is received from the wireless data transceiving station. The receiver module adjusts a data transmission condition based on a transmission distance by detecting intensity of the pilot signal and calculating the transmission distance corresponding to the detected intensity.
Bosentan is metabolized by CYP2C9 and CYP3A. Inhibition of these enzymes may increase the plasma concentration of bosentan [see Pharmacokinetics (12.3)]. Concomitant administration of both a CYP2C9 inhibitor (such as fluconazole or amiodarone) and a strong CYP3A inhibitor (e.g., ketoconazole, itraconazole) or a moderate CYP3A inhibitor (e.g., amprenavir, erythromycin, fluconazole, diltiazem) with bosentan will likely lead to large increases in plasma concentrations of bosentan. Coadministration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with bosentan is not recommended.

Bosentan is an inducer of CYP3A and CYP2C9. Consequently plasma concentrations of drugs metabolized by these two isozymes will be decreased when bosentan is coadministered. Bosentan had no relevant inhibitory effect on any CYP isozyme in vitro (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A). Consequently, bosentan is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.

Figure 1. CYP3A induction-mediated effect of bosentan on other drugs

  


Figure 2. Effect of other drugs on bosentan
Individuals with advanced cancers often experience significant symptom burden including pain, fatigue, and psychological distress, all while facing acceptance of the meaning of their advanced disease. Evidence-based behavioral interventions have been developed to alleviate this multiple symptom burden but are understudied and the treatments that are available are often not easily accessed by patients most in need in community-based settings. The current study examines the feasibility and acceptability of an open trial of mindfulness-based Cognitive Behavioral Therapy intervention delivered via telephone to men and women age 21 and older with a diagnosis of advanced cancer. Potential participants (N=35) will be recruited via letter from their oncologist at community-based clinics (N=18) and those served at the Duke Cancer Institute in Durham who live more than 60 miles away (N=17). Following informed consent, participants will be asked to complete assessments (e..g., examining their pain, anxiety, depression, fatigue, and engagement in valued activity). They will then receive 4 weekly 50-minute telephone sessions with a study therapist and practice skills learned in session at home. After completing the 4 sessions, they will complete a post-treatment assessment. Data analyses will examine the feasibility and acceptability of the study by assessing participant engagement, and will examine changes in key psychological variables (e.g., pain, anxiety, depression, fatigue, and valued activity) from baseline to post-treatment. There is minimal risk related to confidentiality of data and the possibility of feeling uncomfortable in the study. All study contacts will be conducted by trained study staff and supervised by the PI; a licensed clinical psychologist. Participant tracking data will be stored online via REDCAP and accessed only by study staff, participant assessment data will be collected and stored online via REDCap, and audio recordings of study telephone sessions will be stored on Duke servers.
There is no safe and effective treatment for DiGeorge syndrome and most patients die by the age of two. Complete DiGeorge syndrome is characterized by very low T cell or very low naïve T cell numbers. In this study, typical complete DiGeorge syndrome subjects underwent human postnatal cultured thymus tissue implantation (CTTI). Thymus tissue that would otherwise be discarded was processed and then implanted into complete DiGeorge subjects in the operating room. At the time of CTTI, a skin biopsy may have been obtained to look for any preexisting T cells. After CTTI, subjects were followed by routine research immune evaluations, using blood samples obtained approximately every 2-4 weeks. At approximately 2-3 months post-CTTI subjects underwent an open biopsy of the allograft. The biopsy was done under general anesthesia in the operating room. At the time of the graft biopsy, another skin biopsy was obtained to look for clonal populations of T cells.

The protocol aims include: assessing thymopoiesis in the allograft biopsy; assessing immunoreconstitution of complete DiGeorge syndrome subjects after postnatal allogeneic cultured thymus tissue implantation; assessing minimally invasive methods of assessing thymopoiesis (flow cytometry and polymerase chain reaction (PCR); assessing pre-implant T cells which do not proliferate in response to mitogens (focusing on NK-T cells); and, assessing cultured thymus tissue implantation safety and toxicity.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to dermatocosmetology, and can be used in treatment of dehydrated involutionally changed face skin in women. For this purpose the first stage successive complex morphofunctional examination of state of moisture-holding structures of epidermal and dermal face skin layers with estimation of their dehydration degree is carried out. First, epidermal layer is examined. If indices of corneal layer moisture degree are lower than 30 conv.units CM, those of moisture-holding function of epidermis are higher than 13 gram/hour/m, degree of relief is higher than 25 conv.units, wrinkling is higher than 20 conv.units, porosity is 23 conv.units, as well as presence of roughness and thinning of epidermis contours, reduction of its echogenesity, smoothing of boundary between epidermis and derma with absence of changes in dermal structures, structural and functional disorders of epidermis with expressed dehydration are diagnosed. After that, state of moisture-holding structures of dermal skin layer is analysed. Degree of its elasticity, presence or absence of homogeneity, thickness and state of dermoepidermal connection are determined. In case of value of dermal structure elasticity indexes lower than 50%, reduction of derma thickness below index value 1.67±0.381, detection of non-homogeneity of dermal structures, development of hypoechogenic zones, structural and functional disorders of derma with expressed dehydration are diagnosed. Then, correction of dehydrated involutionally changed skin is carried out. In case if structural and functional disorders of epidermis are present, preparation "Hyalrepair-07M/mesolift" with concentration of hyaluronic acid 2 mg/ml is introduced intradermally in dose 1 ml on face area 1 time per week, the course includes 5 procedures. In case if structural and functional disorders of derma and epidermis are present, preparation "Hyalrepair-02 bioreparant" with concentration of hyaluronic acid 14 mg/ml is introduced in dose 1 ml on face area 1 time per 3 weeks, the course includes 3 procedures.EFFECT: method ensures obtaining stable and expressed therapeutic effect in case of introduction of hyaluronic acid preparations due to identification and taking into account determined parameters.1 tbl, 2 ex
Participants will complete three flight simulator tasks at a simulated 8,000 foot altitude. During the flight simulator, participants will need to accomplish three tasks: 1) Maintaining an altitude of 5,000 ft of elevation while performing a mental math test, 2) Flying the aircraft through the center of a series of 7 targets, and 3) Taking off and flying the aircraft a short distance to land on the center of an indicated target.
1. Normal diet: the course of treatment was 4 days. The subjects were asked to record the daily diet and dietary intake in the daily observation scale (Table 1).
2. High control diet intervention: the course of treatment was 31 days. According to the actual intake of calories, 2 / 3, 1 / 2, 1 / 3 and 1 / 4 of the actual intake of the subjects were calculated as the light fasting calories. The treatment course of each calorie stage was 4 days. The subjects recorded the daily diet and dietary intake, and the nutritionists calculated the daily calorie intake and dietary types of each subject according to the daily calorie intake of each subject's normal diet. During the period of high control diet intervention, the diet on the day of light fasting was provided by the research group. Besides the diet provided by the research group, other foods (except water without calories) were strictly prohibited on the day of light fasting.
3. Low control diet intervention: the course of treatment was 31 days. It is suggested that the calorie intake of men and women should be 600 kcal / day and 500 kcal / day on the day of light fasting. The diet type can refer to the recipe made by the nutritionist.
INTRODUCTION: Studies in recent years have shown that high uric acid causes harm to the human body, which has become a serious public health problem. Elevated serum uric acid has been shown to be associated with obesity, but the relationship between BMI and uric acid (UA) remains controversial. Although the association between BMI and UA has been well studied, the effect of phosphorus levels in vivo on this association remains unclear. This study aimed to determine the relationship between BMI and serum uric acid and the effect of phosphorus on the relationship between the two.
RESEARCH DESIGN AND METHODS: The present study analyzed data from the National Health and Nutrition Examination Survey (NHANES) continuous 2007-2018 cycle. We included 10786 participants aged 20 years and over. Multivariable linear regression was performed to assess the association between BMI and serum uric acid. phosphorus was stratified into low phosphorus (<3.3 mg/dl), middle phosphorus (3.3-3.9 mg/dl) and high phosphorus (>3.9 mg/dl). Correction of the effect of phosphorus was assessed by testing the interaction between BMI and UA in multivariate linear regression.
RESULTS: In this cross-sectional study, we found that BMI was positively associated with UA in the female population but not significantly in the male population or in the total population. In multiple regression analysis, UA was 0.51 higher in the highest female BMI group than in the lowest group (p = 0.0001). The relationship between BMI and UA differed significantly by gender under the influence of phosphorus, with men and women in Model II having a greater elevation of UA in men than in women within most groups. (BMI >30, phosphorus >3.9 mg/dl, β:0.83 95% CI: 0.43, 1.23 vs β: 0.79 95% CI: 0.30, 1.29). In addition, phosphorus significantly altered the positive association between BMI and UA in most models.
CONCLUSION: Our results indicate significant associations between BMI and uric acid in women, with higher BMI values likely to be associated with a higher risk of hyperuricemia, suggesting that uric acid levels in obese people should be closely monitored in clinical practice. Phosphorus and BMI have an interactive effect in elevating UA and should be noted as indicators of phosphorus in clinical practice.
A confectionery product which is a chewing gum produces an unusual and amusing effect of foaming and frothing in the mouth when it is chewed. The gum is coated with a sugary edible weak acid containing layer and a sugary edible weak base containing layer. The acid and based layers are separated from one another by a hard, sugary layer which acts as a barrier between the acid and base layers and which prevents the acid and base coming into contact with one another during storage. Once the barrier layer is broken on chewing of the gum product, the acid and base react with the generation of carbon dioxide to give the foaming effect. Typically, the base comprises bicarbonate of soda dispersed in dextrose in an amount of between 2% and 10% w/w of dry powder mixture. The acid typically comprises citric acid dispersed in dextrose in an amount of between 2% and 10% w/w of dry powder mixture.
The experimental design combined MBSR with an environmental condition. Participants were randomly assigned to brief MBSR in one of the three different environments (i.e., natural outdoor environment, built outdoor environment and indoor environment). All participants were asked to attend the brief MBSR programme for 6 weeks with 1-hour sessions. The weekly MBSR session included sitting and body scanning meditation, mindfulness exercises and group discussion led by a qualified mindfulness facilitator. During the experiment, participants were asked to complete the same questions in DASS-21 four times: baseline, after 3 weeks, after 6 weeks (at the completion of the 6-week MBSR) and one-month follow-up. In addition, participants who attended at least five of the six MBSR sessions were invited to donate their hair samples to measure the change of their stress level.
Patients diagnosed with both Type II Diabetes Mellitus and COVID-19 will be in this group. No additional intervention will be applied in this group except the routine COVID-19 treatments according to the Adult Patient Treatment Guide which published by the Ministry of Health, Republic of Turkey on 9 October 2020 and routine treatment for Type II Diabetes Mellitus.
The present invention relates to a novel tripeptide, expressed by the following formula 1, and to a cosmetic composition comprising same as an active ingredient for preventing skin aging, reducing skin wrinkles, whitening, and anti-inflammation. According to the present invention, the tripeptide exhibits wrinkle-preventing effects due to the inhibition of MMPs, which are collagen-degrading enzymes, and the effect of enhancing the production and biosynthesis of collagen. Also, the tripeptide exhibits a whitening effect, such as preventing skin-pigmentation phenomena, through the effect of inhibiting tyrosinase activity and the inhibition of melanin production, and the tripeptide exhibits an inflammation-suppressing effect. Thus, the tripeptide provides a cosmetic which is highly effective at reducing wrinkles, whitening, and preventing inflammation. More particularly, the tripeptide for preventing wrinkles and for whitening can be used by being added to various cosmetic skincare compositions, such as skin ointments, lotions, creams, foundation, essences, gels, packs, foam cleansers, body oils, lipstick, mascara, makeup bases, or soaps. Also, the tripeptide has the properties of not being a skin irritant and having excellent stability on the skin. Formula 1: R 1 -X-Leu-Phe (wherein, in formula 1, R 1  is an alkenyl group selected from among hydrogen or an acyl group having 1 to 18 carbon atom(s) comprising at least one double bond. Leu may be D-Leu or L-Leu, while Phe may be D-Phe or L-Phe. Also, the X position in formula 1 may be selected from among the amino acids, particularly, 20 natural amino acids and phenylglycine, which is an artificial amino acid, and the c-terminal thereof may be carboxylic acid or an amide.)
General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity characterised by mechanical allodynia and thermal hyperalgesia, without any licensed medications. ART26.12 is a fatty acid-binding protein (FABP) 5 inhibitor with antinociceptive properties, characterised here for the prevention and treatment of OIPN. ART26.12 binds selectively to FABP5 compared to FABP3, FABP4, and FABP7, with minimal off-target liabilities, high oral bioavailability, and a NOAEL of 1,000 mg/kg/day in rats and dogs. In an established preclinical OIPN model, acute oral dosing (25-100 mg/kg) showed a cannabinoid receptor type 1 (CB1)-dependent anti-allodynic effect lasting up to 8 hours (persisting longer than plasma exposure to ART26.12). Antagonists of cannabinoid receptor type 2 (CB2), peroxisome proliferator-activated receptor alpha, and transient receptor potential cation channel subfamily V member 1 (TRPV1) may have also been implicated. Twice daily oral dosing (25 mg/kg bis in die (BID) for 7 days) showed anti-allodynic effects in an established OIPN model without the development of tolerance. In a prevention paradigm, coadministration of ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss. Multi-scale analyses revealed widespread lipid modulation, particularly among N-acyl amino acids in the spinal cord, including potential analgesic mediators. Additionally, ART26.12 administration led to upregulation of ion channels in the periaqueductal grey, and broad translational upregulation within the plasma proteome. These results show promise that ART26.12 is a safe and well-tolerated candidate for the treatment and prevention of OIPN through lipid modulation. PERSPECTIVE: Inhibition of fatty acid-binding protein 5 (FABP5) is a novel target for reducing pain associated with chemotherapy. ART26.12 is a safe and well-tolerated small molecule FABP5 inhibitor effective at preventing and reducing pain induced with oxaliplatin through lipid modulation and activation of cannabinoid receptors.
Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anti-cancer active agent, for example 131I, 125I, 124I, or 123I, or a chemotherapeutic agent.
Subjects who respond favorably to test/trial stimulation of the insula will be implanted with DBS devices. In an outpatient clinical trial, each subject will receive 3 months of active stimulation and 3 months of sham stimulation. The assignment for stimulation will be randomized and blinded to the subject and to the outcome assessors.
OBJECTIVE: Hemifacial spasm (HFS) is a movement disorder characterized by involuntary muscle contractions on one side of the face. It is associated with disturbances in the brain's functional architecture. Despite this, the structural alterations in the brain related to HFS remain poorly understood. In this study, we investigated the cortical morphology changes in patients with HFS compared to healthy controls (HCs).
METHODS: We analyzed 3D T1-weighted MRI images from 33 patients with left-sided primary HFS and 33 age- and sex-matched HCs. Measurements of cortical thickness (CTh), sulcal depth, local gyrification index (lGI), and fractal dimension were taken using a computational anatomy toolbox. A general linear model, accounting for age, gender, and total brain volume, was applied for statistical analyses. Significant clusters were then assessed for correlations with clinical parameters.
RESULTS: The HFS patients displayed several cortical abnormalities when compared to HCs, including reduced CTh in the contralateral precentral gyrus and left orbitofrontal cortex, decreased sulcal depth in the left orbitofrontal cortex, and increased lGI in the right insula and superior temporal cortex. However, fractal dimension did not differ significantly between the groups. Additionally, in HFS patients, a notable negative correlation was found between the sulcal depth in the left orbitofrontal cortex and the Beck Depression Inventory-II scores.
CONCLUSIONS: Our findings reveal that HFS is associated with specific surface-based morphological changes in the brain. These alterations contribute to a deeper understanding of the neurophysiological mechanisms involved in HFS and may have implications for future research and treatment strategies.
Retifanlimab was administered once every 4 weeks on a 28-day cycle as an open-label product, at an initial dose of 500 mg over a 60-minute intravenous infusion. Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.